The Decision Behind the Prescription in 1L EGFR+ NSCLC

Ten oncologist conversations via Patient Scribe — what the clinical reasoning behind 1L prescribing in EGFR-mutant NSCLC reveals about disease burden thresholds, patient preference, formulation timing, and how fast the standard of care is shifting. 

About Patient Scribe

Patient Scribe is ZoomRx’s AI-powered conversational chart audit platform. Rather than asking physicians to complete a structured form, it conducts a voice-first conversation — letting them describe patient cases in their own clinical language. The AI listens, follows up when reasoning surfaces, and structures the output. What gets captured is the decision logic behind the prescription, not just the prescription itself.

Drugs in scope: Rybrevant + Lazcluze (amivantamab + lazertinib) · Tagrisso (osimertinib) monotherapy · Tagrisso + chemotherapy

What This Study Was Designed to Answer

Ten oncologists managing 1L EGFR-mutant mNSCLC patients were recruited across academic and community settings. The study was designed to surface answers to four key business questions:

• What clinical and patient factors drive the choice between Rybrevant + Lazcluze and Tagrisso-based regimens in 1L EGFR+ mNSCLC?
• What role do patient preferences, performance status, and access considerations play in regimen selection — and how often do they override clinical preference?
• How is the availability of the subcutaneous amivantamab formulation changing the tolerability calculus for Rybrevant + Lazcluze?
  

What the Conversations Reveal That the Charts Don’t

THE DECISION IS A RISK STRATIFICATION, NOT A DRUG COMPARISON 

Across the Rybrevant + Lazcluze cases in this dataset, the prescribing decision was not primarily a drug comparison. It was a risk stratification: high disease burden, CNS involvement, or anticipated resistance put a patient in the combination group. Performance status and patient-stated constraints put a patient in the Tagrisso group. Traditional PCAs capture the outcome of that stratification — not the stratification itself. A brand team reading this data without the conversation sees a market split. With the conversation, they see the criteria that determine which side of the split a patient lands on. 

A FORMULATION GAP, NOT A CLINICAL GAP, COST ONE PRESCRIPTION 

One prescription in this dataset was explicitly lost to IV formulation tolerability. The physician preferred Rybrevant + Lazcluze on clinical grounds, evaluated it seriously, and prescribed something else because the SubQ formulation was not yet available and the IV AE profile was the barrier. That is not a messaging problem or an awareness problem. It is a formulation access problem — and it is structurally invisible in prescribing data. The SubQ launch changes this calculus. The physicians who previously passed on the IV regimen for tolerability reasons are the most commercially actionable audience. 

THE STANDARD IS SHIFTING — FASTER THAN PRESCRIBING DATA REFLECTS 

Two forces are pulling the 1L standard toward combination therapy in this indication. The first is trial data: Mariposa is being cited by name as the reason Tagrisso monotherapy is no longer the default for high-risk patients. The second is time: physicians treating patients diagnosed in 2020 or 2021 under a previous standard are now looking at those same patients and noting that the decision would be different today. The addressable pool for Rybrevant + Lazcluze in 1L is expanding — not because the drug changed, but because the evidence threshold that justifies the combination is now more widely accepted. 

The Cases Behind the Insights

Rybrevant + Lazcluze — What Drove the Decision

P2 — 68F | STAGE 4B | EXON 19 DELETION | NEVER SMOKER | ACADEMIC CENTER → RYBREVANT + LAZCLUZE 
68-year-old female. Stage 4B. EGFR exon 19 deletion. Never smoker. Medicare. Highly motivated. 

The physician cited Mariposa trial data as the primary rationale over Tagrisso monotherapy. High disease burden and the need to maximize PFS drove the decision toward the combination. Tagrisso was explicitly considered and set aside on the strength of the trial evidence. The prescribing record captures the current regimen. It does not capture that this was an active, evidence-driven choice between two specific options — or that Mariposa data, not clinical differentiation alone, was the deciding argument. 

P3 — 53F | STAGE IV WITH CNS METASTASIS | EXON 19 DELETION | NEVER SMOKER | ACADEMIC CENTER → RYBREVANT + LAZCLUZE 
53-year-old female. Stage IV. Exon 19 deletion. Baseline CNS metastasis. Commercial insurance. 

Two factors converged on the combination regimen: CNS disease control was the primary clinical driver, and the patient wanted to minimize hospital visits to maintain quality of life. The prescribing logic was mechanism and QoL simultaneously — the combination addressed the CNS risk that Tagrisso monotherapy would not resolve as robustly, and the regimen’s administration schedule aligned with the patient’s preference. Neither the CNS rationale nor the patient’s QoL consideration appears in the structured Rx field. 

P7 — 46M | METASTATIC WITH BRAIN METS | L858R | COMMERCIAL | ACADEMIC CENTER → RYBREVANT + LAZCLUZE 
46-year-old male. Metastatic NSCLC with brain metastasis. EGFR L858R. Commercial insurance. 

Young patient. The physician’s rationale extended beyond current efficacy to anticipated resistance: amivantamab was selected in part because it “prophylactically addressed MET amplification” — a known downstream resistance mechanism in EGFR-mutant disease. Durable PFS for a patient with significant life expectancy ahead was the framing. A prescribing record shows a regimen change. It does not show that resistance preemption — not current disease control alone — was part of the clinical rationale. 

 “I used this medication because amivantamab had been approved a year prior and was an effective medication that mechanistically addressed common causes of resistance in EGFR mutated non-small cell lung carcinoma.”
— Oncologist, EGFR+ NSCLC patient audit (P7) — Rybrevant + Lazcluze

Tagrisso — What Kept the Combination Off the Table

P4 — 64M | METASTATIC (BONE ONLY) | EXON 19 | MEDICARE | PRIVATE PRACTICE → TAGRISSO + CHEMOTHERAPY 
64-year-old male. Single bone lesion. EGFR exon 19. Medicare. Private practice. 

Rybrevant + Lazcluze was actively considered for this patient and rejected. The reason was not clinical preference for Tagrisso — it was the IV formulation’s AE profile. Infusion reactions and skin toxicity made the IV regimen unsuitable. The SubQ formulation was not yet available at the time of the prescription. Tagrisso + chemotherapy was initiated instead. The prescribing record shows a Tagrisso + chemotherapy initiation. It does not show that Rybrevant + Lazcluze was the preferred choice and that a formulation timing gap was the reason it was not prescribed. 

 “I have significant concerns about the tolerability of the IV formulation as the sub Q formulation was not available at the time.”
— Oncologist, EGFR+ NSCLC patient audit (P4) — Rybrevant + Lazcluze passed over

P6 — 69F | METASTATIC | EXON 19 | MEDICARE | ACADEMIC CENTER → TAGRISSO MONOTHERAPY 
69-year-old female. Metastatic. Exon 19. Poor performance status. Medicare.

Performance status was the single deciding factor. Rybrevant + Lazcluze was considered and set aside — not on clinical grounds specific to the regimen, but because the combination’s demands were inconsistent with a patient whose performance status precluded it. Single-agent Tagrisso was the appropriate step given where the patient was. A checkbox records a Tagrisso monotherapy initiation. It does not record that performance status was the gate that kept a combination regimen off the table. 

P8 — 56M | STAGE 3A | EXON 19 | VA INSURANCE | VA HOSPITAL → TAGRISSO MONOTHERAPY 
56-year-old male. Stage 3A, incidentally found. Exon 19. VA healthcare coverage. 

The patient made the boundaries of treatment explicit before the clinical conversation reached regimen selection: no chemotherapy, no surgery, no radiation. Tagrisso monotherapy was the appropriate choice within those constraints, and the physician framed it around overall survival benefit while respecting patient-stated goals. The prescribing record shows a Tagrisso initiation. It does not show that patient preference eliminated combination therapy as an option before it was clinically evaluated. 

P10 — 59M | STAGE IV WITH CNS METS | EXON 21 L858R | UNINSURED | ACADEMIC CENTER → TAGRISSO MONOTHERAPY 
59-year-old male. Stage IV. Exon 21 L858R. CNS metastasis. Uninsured. Diagnosed 2020. 

CNS penetration drove the choice of Tagrisso over earlier-generation TKIs. At the time of diagnosis — 2020 — monotherapy was standard of care. The physician volunteered that the same patient diagnosed today would likely receive combination therapy. Lack of insurance added an access dimension: oral therapy was logistically appropriate given transportation constraints, and AZ&ME support resolved the payer gap. The chart records a Tagrisso prescription from 2020. It records neither the era of diagnosis that shaped the decision nor the access barrier that made oral therapy the right format. 

 “If this patient were diagnosed more recently, I think a combination with chemotherapy would be indicated.”
— Oncologist, EGFR+ NSCLC patient audit (P10) — reflecting on 2020 standard of care

Why the Conversation Changes What a Brand Team Can Do

Ten conversations. A market that looks evenly split in prescribing data but is actually governed by specific, identifiable criteria — disease burden, CNS risk, performance status, patient goals, and formulation timing. The commercial strategy that acts on those criteria is different from the one that acts on aggregate share numbers. The conversation is where the difference lives.

A traditional PCA in this indication produces a prescription count. Patient Scribe produces a reasoning distribution — how many physicians are selecting Rybrevant+Lazertinib because of CNS activity, how many because their center adopted it early, how many because their trial familiarity runs in that direction. Each of those physician segments has a different commercial trigger. Treating them as one because they wrote the same Rx misses the actual structure of the market.

The richer future is not more questions on the same form. It is research designed to let the physician explain — and structured analysis that recovers the clinical logic from the explanation. In an indication where the decision happens between two appropriate, guideline-supported options, the conversation is not supplementary. It is the evidence.

See What Patient Scribe Would Uncover for Your Brand

ZoomRx is offering a zero-cost pilot wave for teams who want to see what Patient Scribe surfaces for their brand. Same rigor as a full PCA study, no commitment required.